此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)

2026年11月9日 更新者:EyeBiotech Ltd.

一项随机、双盲、多中心、3 组关键 2/3 期研究,旨在评估玻璃体内注射 EYE103 与玻璃体内注射雷珠单抗 (0.5mg) 相比,对糖尿病黄斑水肿参与者的疗效和安全性

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)

In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.

Approximately 960 participants will be entered in the study.

研究概览

详细说明

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)

Approximately 960 participants will be entered in the study. Participants will be randomized 1:1:1 to receive low dose remigromig, high dose remigromig, or 0.5 mg ranibizumab, administered via intravitreal injection. In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. Throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA), examination by slit-lamp biomicroscopy, fundoscopy, and spectral domain optical coherence tomography (SD-OCT). Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns.

研究类型

介入性

注册 (实际的)

984

阶段

  • 阶段2
  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Be’er Ya‘aqov、以色列、70300
        • Beer Yakov, Israel
      • Haifa、以色列、3436212
        • Haifa, Israel
      • Jerusalem、以色列、9112001
        • Jerusalem, Israel
      • Petah Tikva、以色列、49100
        • Petah Tikva, Israel
      • Rehovot、以色列、76100
        • Rehovot, Israel
      • Tel Aviv、以色列、6423906
        • Tel Aviv, Israel
      • Osijek、克罗地亚、31000
        • Osijek, Croatia
      • Budapest、匈牙利、H-1062
        • Budapest, Hungary
      • Budapest、匈牙利、H-1085
        • Budapest, Hungary
      • Budapest、匈牙利、H-1106
        • Budapest, Hungary
      • Budapest、匈牙利、H-1133
        • Budapest, Hungry
      • Debrecen、匈牙利、H-4032
        • Debrecen, Hungary
      • Pécs、匈牙利、H-7621
        • Pecs, Hungary
      • Szeged、匈牙利、H-6720
        • Szeged, Hungary
      • Zalaegerszeg、匈牙利、8900
        • Zalaegerszeg, Hungary
      • Medellín、哥伦比亚、50016
        • Medellin, Colombia
    • Antioquia
      • Medellín、Antioquia、哥伦比亚、50021
        • Medellin, Colombia
    • Atlántico
      • Barranquilla、Atlántico、哥伦比亚、80002
        • Barranquilla, Colombia
    • Columbia
      • Bogotá、Columbia、哥伦比亚、110231
        • Bogota, Columbia
    • Valle del Cauca Department
      • Cali、Valle del Cauca Department、哥伦比亚、760042
        • Cali, Colombia
    • Turkey
      • Ankara、Turkey、土耳其(türkiye)、06230
        • Ankara, Turkey
      • Ankara、Turkey、土耳其(türkiye)、06490
        • Ankara, Turkey
      • Balçova、Turkey、土耳其(türkiye)、35330
        • Balcova, Turkey
      • Graz、奥地利、8036
        • Graz, Austria
      • Innsbruck、奥地利、6020
        • Innsbruck, Austria
      • Vienna、奥地利、1090
        • Vienna, Austria
      • Vienna、奥地利、1140
        • Vienna, Austria
      • Frankfurt、德国、60590
        • Frankfurt, Germany
      • Hanover、德国、30625
        • Hanover, Germany
      • München、德国、80336
        • Munchen, Germany
      • Münster、德国、48145
        • Munster, Germany
      • Bologna、意大利、40138
        • Bologna, Italy
      • Florence、意大利、50139
        • Firenze, Italy
      • Milan、意大利、20122
        • Milano, Italy
      • Milan、意大利、20132
        • Milano, Italy
      • Milan、意大利、20157
        • Milano, Italy
      • Roma、意大利、00168
        • Roma, Italy
      • Rome、意大利、81.00133
        • Rome, Italy
      • Udine、意大利、33100
        • Udine, Italy
      • Riga、拉脱维亚、LV1002
        • Riga, Latvia
      • Riga、拉脱维亚、LV1006
        • Riga, Latvia
      • Mladá Boleslav、捷克语、293 01
        • Mlada Boleslav, Czechia
      • Náchod、捷克语、547 01
        • Nachod, Czechia
      • Prague、捷克语、1150/50
        • Prague, Czechia
      • Prague、捷克语
        • Prague, Czechia
      • Trebišov、斯洛伐克、075 01
        • Trebisov, Slovakia
      • Trenčín、斯洛伐克、911 01
        • Trencin, Slovakia
      • Žilina、斯洛伐克、012 07
        • Zilina, Slovakia
      • Créteil、法国、94010
        • Creteil, France
      • Lyon、法国、69004
        • Lyon, France
      • Marseille、法国、13008
        • Marseille, France
      • Paris、法国、75006
        • Paris, France
      • Paris、法国、75015
        • Paris, France
      • Paris、法国、75019
        • Paris, France
      • Saint-Cyr-sur-Loire、法国、37540
        • Saint Cyr sur Loire, France
    • Cedex
      • Dijon、Cedex、法国、21079
        • Cedex, France
      • Bialystok、波兰、15-866
        • Bialystok, Poland
      • Bydgoszcz、波兰、85-309
        • Bydgoszcz, Poland
      • Bydgoszcz、波兰、85-631
        • Bydgoszcz, Poland
      • Gdansk、波兰、80-809
        • Gdansk, Poland
      • Katowice、波兰、40-594
        • Katowice, Poland
      • Krakow、波兰、31-501
        • Krakow, Poland
      • Olsztyn、波兰、10-424
        • Olsztyn, Poland
      • Tarnowskie Góry、波兰、42-600
        • Tarnowskie Gory, Poland
    • Gdansk
      • Gdansk、Gdansk、波兰、80-809
        • Gdansk, Poland
    • PR
      • Arecibo、PR、波多黎各、00612
        • Arecibo, PR
      • Albury、澳大利亚、2640
        • Albury, Australia
      • Parramatta、澳大利亚、2150
        • Parramatta, Australia
      • Sydney、澳大利亚、2000
        • Sydney, Australia
    • New South Wales
      • Sydney、New South Wales、澳大利亚、2000
        • Sydney Retina Clinic
      • Sydney、New South Wales、澳大利亚、2135
        • Sydney, Australia
    • Arizona
      • Scottsdale、Arizona、美国、85255
        • Scottsdale
    • Arkansas
      • Fayetteville、Arkansas、美国、72703
        • Fayetteville, Arkansas
      • Springdale、Arkansas、美国、72764
        • Springdale, Arkansas
    • California
      • Bakersfield、California、美国、93309
        • Bakersfield, CA
      • Glendale、California、美国、91204
        • Glendale, CA
      • Modesto、California、美国、95356
        • Modesto, CA
      • Mountain View、California、美国、94040
        • Mountain View, CA
      • Redlands、California、美国、92374
        • Redlands, CA
      • Sacramento、California、美国、95825
        • Sacramento, CA
      • Sacramento、California、美国、95841
        • Sacramento, CA
      • Santa Ana、California、美国、92705
        • Santa Ana
    • Colorado
      • Colorado Springs、Colorado、美国、80909
        • Colorado Springs, CO
      • Denver、Colorado、美国、80210
        • Denver, Colorado
    • Connecticut
      • Danbury、Connecticut、美国、06810
        • Danbury, CT
      • Manchester、Connecticut、美国、06042
        • Manchester, CT
      • Waterford、Connecticut、美国、06385
        • Waterford,CT
    • Florida
      • Deerfield Beach、Florida、美国、33064
        • Deerfield Beach, FL
      • Fort Lauderdale、Florida、美国、33308
        • Fort Lauderdale, FL
      • Fort Myers、Florida、美国、33912
        • Fort Myers,FL
      • Gainesville、Florida、美国、32607
        • Gainesville, FL
      • Orlando、Florida、美国、32806
        • Orlando, Florida
      • Plantation、Florida、美国、33324
        • Plantation, FL
      • Sarasota、Florida、美国、34232
        • Sarasota, FL
      • St. Petersburg、Florida、美国、33711
        • Saint Petersburg, FL
      • Tallahassee、Florida、美国、32308
        • Tallahassee, FL
      • Tampa、Florida、美国、33609-4614
        • Tampa, FL
      • Tampa、Florida、美国、33617
        • Tampa, FL
      • Winter Haven、Florida、美国、33880
        • Winter Haven, FL
    • Illinois
      • Lemont、Illinois、美国、60439
        • Lemont, IL
      • Springfield、Illinois、美国、62702
        • Springfield, Illinois
    • Iowa
      • West Des Moines、Iowa、美国、50266
        • West Des Moines, IA
    • Kansas
      • Lenexa、Kansas、美国、66215
        • Lenexa, Kansas
      • Wichita、Kansas、美国、67214
        • Wichita, Kansas
    • Maine
      • Portland、Maine、美国、04101
        • Portland, Maine
    • Maryland
      • Hagerstown、Maryland、美国、21740
        • Hagerstown, MD
    • Massachusetts
      • Springfield、Massachusetts、美国、01107
        • Springfield,MA
    • Michigan
      • Grand Rapids、Michigan、美国、49546
        • Grand Rapids, Michigan
    • Minnesota
      • Minneapolis、Minnesota、美国、55435
        • Minneapolis, MN
    • Mississippi
      • Madison、Mississippi、美国、39110
        • Madison, MS
    • New Jersey
      • Bloomfield、New Jersey、美国、07003
        • Bloomfield, NJ
      • Cherry Hill、New Jersey、美国、08034
        • Cherry Hill, NJ
    • New York
      • Liverpool、New York、美国、13088
        • Liverpool, NY
      • Oceanside、New York、美国、11572
        • Oceanside, NY
      • Rochester、New York、美国、14620
        • Rochester, NY
    • North Carolina
      • Asheville、North Carolina、美国、28803
        • Asheville, NC
      • Hickory、North Carolina、美国、28602
        • Hickory, NC
      • Wake Forest、North Carolina、美国、27587
        • Wake Forest, MC
      • Winston-Salem、North Carolina、美国、27103
        • Winston Salem, NC
    • Ohio
      • Cleveland、Ohio、美国、44122
        • Cleveland, Ohio
      • Cleveland、Ohio、美国、44130
        • Cleveland, OH
      • Youngstown、Ohio、美国、44505
        • Youngstown, Ohio
    • Oklahoma
      • Edmond、Oklahoma、美国、73013
        • Edmond, OK
    • Oregon
      • Portland、Oregon、美国、97221
        • Portland, OR
      • Springfield、Oregon、美国、97477
        • Springfield, Oregon
    • Pennsylvania
      • Bethlehem、Pennsylvania、美国、18017
        • Bethlehem, PA
      • Erie、Pennsylvania、美国、16507
        • Erie, PA
    • South Carolina
      • Beaufort、South Carolina、美国、29902
        • Beaufort, SC
      • Florence、South Carolina、美国、29501
        • Florence, SC
      • Ladson、South Carolina、美国、29456
        • Ladson, SC
      • West Columbia、South Carolina、美国、29169
        • West Columbia, SC
    • Tennessee
      • Germantown、Tennessee、美国、38138
        • Germantown, TN
      • Hixson、Tennessee、美国、37343
        • Hixson, Tennessee
      • Johnson City、Tennessee、美国、37604
        • Johnson City, Tennessee
      • Knoxville、Tennessee、美国、37922
        • Knoxville, TN
      • Nashville、Tennessee、美国、37203
        • Nashville, TN
    • Texas
      • Abilene、Texas、美国、79606
        • Abilene, TX
      • Amarillo、Texas、美国、79109
        • Amarillo, TX
      • Amarillo、Texas、美国、79106
        • Amarillo, TX
      • Arlington、Texas、美国、76012
        • Arlington, TX
      • Austin、Texas、美国、78705
        • Austin, TX
      • Beaumont、Texas、美国、77707
        • Beaumont, TX
      • Bellaire、Texas、美国、77401
        • Bellaire, TX
      • Dallas、Texas、美国、75231
        • Dallas, TX
      • Fort Worth、Texas、美国、76104
        • Fort Worth, TX
      • Katy、Texas、美国、77494
        • Katy, TX
      • Plano、Texas、美国、75075
        • Plano, TX
      • Round Rock、Texas、美国、78681
        • Round Rock, TX
      • San Antonio、Texas、美国、78240
        • San Antonio, TX
      • Schertz、Texas、美国、78154
        • Schertz, Texas
      • The Woodlands、Texas、美国、77384
        • The Woodlands, TX
      • Willow Park、Texas、美国、76087
        • Willow Park, TX
    • Utah
      • Salt Lake City、Utah、美国、84107
        • Salt Lake City, Utah
    • Virginia
      • Lynchburg、Virginia、美国、24502
        • Lynchburg, VA
      • Richmond、Virginia、美国、23235
        • Richmond, Virginia
    • Washington
      • Spokane、Washington、美国、99204
        • Spokane, WA
      • Bradford、英国、BD9 6RJ
        • Bradford, United Kingdom
      • Bristol、英国、BS1 2LX
        • Bristol, UK
      • Liverpool、英国、L7 8YA
        • Liverpool, United Kingdom
      • Sunderland、英国、SR2 9HP
        • Sunderland, United Kingdom
      • Wolverhampton、英国、WV10 0QP
        • Wolverhamptom, United Kingdom
    • Middlesex
      • London、Middlesex、英国、NW10 7NS
        • London, UK
    • UnitedKingdom
      • York、UnitedKingdom、英国、YO10 4DZ
        • York, United Kingdom
      • Coimbra、葡萄牙、3000-548
        • Coimbra, Portugal
      • Coimbra、葡萄牙、3030-163
        • Coimbra, Portugal
      • Porto、葡萄牙、4200-319
        • Porto, Portugal
      • Barcelona、西班牙、08035
        • Barcelona, Spain
      • Barcelona、西班牙、08021
        • Barcelona, Spain
      • Barcelona、西班牙、08022
        • Barcelona, Spain
      • Barcelona、西班牙、08195
        • Barcelona, Spain
      • Santiago de Compostela、西班牙、15706
        • Santiago de Compostela, Spain
      • Seville、西班牙、41009
        • Sevilla, Spain
      • Zaragoza、西班牙、50009
        • Zaragoza, Spain
    • Valencia
      • Burjassot、Valencia、西班牙、46100
        • Valencia, Spain
      • CABA、阿根廷、1023
        • Buenos Aires, Argentina
      • Córdoba、阿根廷、X5000AAJ
        • Ciudad de Cordoba, Argentina
    • Buenos Aires
      • CABA、Buenos Aires、阿根廷、1015
        • Buenos Aires, Argentina
      • CABA、Buenos Aires、阿根廷、1120
        • Buenos Aires, Argentina
      • CABA、Buenos Aires、阿根廷、C1033AAW
        • Buenos Aires, Argentina
      • Caba、Buenos Aires、阿根廷、C1116ABA
        • Caba, Buenos Aires, Argentina
    • Córdoba Province
      • Córdoba、Córdoba Province、阿根廷、5000
        • Cordoba, Argentina
    • Santa Fe Province
      • Rosario、Santa Fe Province、阿根廷、S2000DSK
        • Santa Fe, Argentina
    • Sante Fe
      • Rosario、Sante Fe、阿根廷、2000
        • Santa Fe, Argentina

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
  • Be male or female ≥18 years of age.
  • Have type 1 or type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%.
  • Have a decrease in vision in the study eye determined by the investigator to be primarily the result of diabetic macular edema (DME).

Exclusion Criteria:

  • Be pregnant or breastfeeding

  • History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening

  • Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening

  • Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)

  • If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:

    • Have had prior treatment in the study eye with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
    • Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept [2 mg], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Remigromig Low Dose Treatment Arm

Remigromig Low Dose Treatment Arm

Remigromig is a humanized antibody formulated for intravitreal administration

其他名称:
  • 恢复
  • EYE103
实验性的:Remigromig High Dose Treatment Arm

Remigromig High Dose Treatment Arm

Remigromig is a humanized antibody formulated for intravitreal administration

其他名称:
  • 恢复
  • EYE103
有源比较器:Ranibizumab Treatment Arm

Ranibizumab Treatment Arm

Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema

其他名称:
  • Lucentis

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
大体时间:Baseline and Week 52

The change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented.

Baseline and Week 52

次要结果测量

结果测量
措施说明
大体时间
Change from Baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52
大体时间:Baseline and Week 52

The change from baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52 will be presented.

Baseline and Week 52
Superiority Hypothesis: Change from Baseline in ETDRS BCVA at Week 52
大体时间:Baseline and Week 52

The Superiority Hypothesis: change from baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented.

Baseline and Week 52
Time to Absence of Diabetic Macular Edema (DME)
大体时间:Up to approximately Week 104

The time to absence of Diabetic Macular Edema (DME) defined as Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) of <300 μm will be presented.

Up to approximately Week 104
Time to Gaining ≥15 ETDRS letters
大体时间:Up to approximately Week 52

The time to gaining ≥15 letters on the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented.

Up to approximately Week 52
Proportion of Participants with Resolution of Macular Leakage on FA at Week 24
大体时间:Up to approximately Week 24

The proportion of participants with resolution of macular leakage on fluorescein angiography (FA), defined as 0 to 1 mm^2, at Week 24 will be presented.

Up to approximately Week 24
Proportion of Participants Without Intraretinal and Subretinal Fluid at the Foveal Center on OCT at Week 52
大体时间:Up to approximately Week 52

The proportion of participants without intraretinal and subretinal fluid at the foveal center on Optical Coherence Tomography (OCT) at Week 52 will be presented.

Up to approximately Week 52
Change from Baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52
大体时间:Baseline and Week 52

The change from baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52 will be presented.

Baseline and Week 52
Proportion of Participants Achieving 20/40 or Better BCVA at Week 52
大体时间:Up to approximately Week 52

The proportion of participants who achieve 20/40 or better Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented.

Up to approximately Week 52
Number of Participants Who Experience an Ocular and/or Systemic Adverse Event (AE)
大体时间:Up to approximately 104 Weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic AE will be reported.

Up to approximately 104 Weeks
Number of Participants Who Experience an Ocular and/or Systemic Serious Adverse Event (SAE)
大体时间:Up to approximately 104 Weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic serious adverse event (SAE) will be reported.

Up to approximately 104 Weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
大体时间:Up to approximately 104 Weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

Up to approximately 104 Weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Charles Miller, MD PhD、EyeBiotech Ltd.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年8月7日

初级完成 (实际的)

2026年7月14日

研究完成 (估计的)

2027年8月14日

研究注册日期

首次提交

2024年8月20日

首先提交符合 QC 标准的

2024年8月22日

首次发布 (实际的)

2024年8月26日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅